CD8A and neoplasm: This vaccine delivers full-length p53 to APCs to generate T-cell responses against p53 epitopes and stimulate p53-specific IFN-γ-secreting CD8+ T-cells that proliferate and exhibit cytolytic function against p53-overexpressing tumor cells in vitro.